Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regen BioPharma Inc RGBP

Regen BioPharma Inc. is a biotechnology company. The Company is engaged on the immunology and immunotherapy space. The Company is focused on novel technologies through pre-clinical and Phase I/ II clinical trials. It is involved on mRNA and small molecule therapies for treating cancer and autoimmune disorders. It is also developing products treating blood disorders using small molecules and... see more

Recent & Breaking News (OTCPK:RGBP)

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 22, 2023

PR Newswire February 21, 2023

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 8, 2023

PR Newswire February 7, 2023

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 25, 2023

PR Newswire January 23, 2023

Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio

PR Newswire January 20, 2023

Regen BioPharma, Inc. to address 2023 goals and company direction at the Emerging Growth Conference on January 11, 2023

PR Newswire January 9, 2023

Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer

PR Newswire December 19, 2022

Regen BioPharma Appoints Two New Scientific Advisory Board Members

PR Newswire December 7, 2022

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 30, 2022

PR Newswire November 28, 2022

Regen BioPharma, Inc. Progresses Its DuraCAR Therapeutic

PR Newswire November 18, 2022

Regen BioPharma Developing a Non-Exhaustible CAR-T Cell Therapeutic

PR Newswire November 10, 2022

Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 9, 2022

PR Newswire November 2, 2022

Regen BioPharma, Inc. Explores the CAR-T Therapeutic Space

PR Newswire October 26, 2022

Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy

PR Newswire September 19, 2022

Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy

PR Newswire September 13, 2022

Regen BioPharma Develops Novel Means of Using CAR-T cell Immunotherapy to Attack Solid Tumors

PR Newswire August 25, 2022

Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors

PR Newswire August 11, 2022

Regen BioPharma, Inc. Files Provisional Patent Application on Second Generation Survivin mRNA Cancer Immunotherapy Vaccine

PR Newswire July 26, 2022

Regen BioPharma, Inc. Responds to Numerous Requests for Updates on its Intellectual Property (IP) Portfolio

PR Newswire March 16, 2022

Regen BioPharma, Inc. Announces Program to Fast-Track its Checkpoint Inhibitor Program Utilizing Modified mRNA and siRNA Technologies

PR Newswire March 10, 2022

Oncology Pharma, Inc. and Regen BioPharma, Inc. Announce Intent to Jointly Fast Track Development of Modified mRNA anti-Cancer Vaccine

Accesswire February 14, 2022